Monoprost (Latanoprost)

Latanoprost, the active ingredient in Monoprost, is a prostaglandin analog presented as an ophthalmic solution for ocular use. It lowers intra‑ocular pressure and is indicated for open‑angle glaucoma and ocular hypertension in adult patients.

GNH USA supplies Monoprost as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Monoprost belongs to the prostaglandin analog class and is used to manage conditions that involve elevated intra‑ocular pressure. - Open‑angle glaucoma: reduces intra‑ocular pressure to slow disease progression. - Ocular hypertension: lowers intra‑ocular pressure to prevent development of glaucoma. - Elevated intra‑ocular pressure (any cause): helps maintain target pressure and protect optic nerve health.

Common Side Effects: - Eye redness: mild conjunctival hyperemia. - Increased eyelash growth: longer, thicker lashes. - Iris color change: gradual darkening of the iris. - Eye irritation: burning or stinging sensation. - Blurred vision: transient visual disturbance. - Foreign body sensation: feeling of grit in the eye.

Serious or Rare Side Effects: - Severe allergic reaction: swelling, rash, or difficulty breathing. - Uveitis: inflammation of the uveal tract. - Macular edema: swelling of the central retina. - Vision loss: sudden decrease in visual acuity. - Ocular infection: signs of conjunctivitis or keratitis.

Before initiating therapy, clinicians should evaluate ocular health and monitor intra‑ocular pressure regularly. - Assess baseline intra‑ocular pressure: ensure appropriate therapeutic target. - Monitor iris color changes: inform patients of possible permanent darkening. - Avoid use in active ocular inflammation: may exacerbate condition. - Counsel on eyelash growth: discuss cosmetic implications. - Store at room temperature: keep in original container, protect from light and moisture.

Latanoprost may interact with other ocular medications, affecting efficacy or safety. Major Interactions (Avoid): - Concomitant prostaglandin analogs: risk of additive ocular effects. - Non‑steroidal anti‑inflammatory eye drops: may reduce latanoprost efficacy. Moderate Interactions (Monitor Closely): - Beta‑blocker eye drops: possible additive intra‑ocular pressure lowering. - Systemic carbonic anhydrase inhibitors: enhanced pressure reduction. - Topical corticosteroids: may counteract latanoprost's effect.